Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Elanco Animal Health (ELAN) has drawn investor attention after recent share price swings, including a 2.1% gain over the past day, a 9.4% decline over the past month, and a 5.7% rise over the past 3 months.
See our latest analysis for Elanco Animal Health.
Looking beyond the latest move, Elanco’s share price return over the past year has coincided with a very strong 1 year total shareholder return of 131.2%, while the 5 year total shareholder return of a 16.8% loss suggests that this recent momentum is a relatively new phase rather than a long running trend.
If Elanco’s recent swing has you thinking about where else capital could work, it may be worth scanning for other healthcare names using our 34 healthcare AI stocks
With Elanco trading at $23.93, sitting below an analyst price target of $28.77 and an indicated intrinsic value gap of about 34%, the key question is whether this signals a genuine opportunity or if the market is already accounting for future growth.
At a last close of $23.93 against a narrative fair value of $25.92, Elanco is framed as modestly undervalued, with the storyline hinging on new launches, revenue efforts and balance sheet progress.
The successful launch of six potential blockbuster products and exceeding innovation revenue targets for 2024 positions Elanco for strong innovation contributions in 2025, expected to increase innovation revenue, positively influencing earnings.
Want to see what sits behind this confidence in new products and profitability? The narrative leans on specific revenue paths, margin assumptions and a richer earnings mix. The full breakdown shows how those pieces are combined to reach that fair value estimate.
Result: Fair Value of $25.92 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, you still need to keep an eye on foreign exchange pressure and the execution risk around new product uptake, as both could unsettle the current thesis.
Find out about the key risks to this Elanco Animal Health narrative.
If this all sounds confident, it is worth checking the numbers yourself and deciding how convincing the rewards really look in your view, starting with the 4 key rewards.
If Elanco has sharpened your focus, do not stop here. Broaden your watchlist now so you do not miss opportunities sitting in plain sight.